Solonsax (@Solonsax)

A recent academic review published in the Journal of Law, Medicine & Ethics examined over two decades of pharmaceutical bribery cases, uncovering repeated patterns of sham consulting contracts, fake educational events, luxury travel, and hidden payments. They write: “The old pharmaceutical bribe was easy to recognize. Drug company reps flew doctors to luxury resorts, paid for lavish dinners, disguised kickbacks as consulting fees, and funded educational events that were little more than sales pitches. In 2023, payments and transfers of value to US physicians totalled US$3.93 billion for direct research, consulting, speaking fees, meals, travel, and investment interests. These individual-level incentives remain remarkably effective. But influencing individual doctors is now only part of the strategy. The real evolution has been the movement of pharmaceutical money further upstream. Today, pharmaceutical funding quietly underwrites the very institutions that generate medical evidence, shape clinical standards, and guide public policy — universities, teaching hospitals, medical journals, research institutes, continuing medical education providers, professional societies, guideline panels, and patient advocacy groups. Instead of paying a doctor to choose a drug, the modern strategy endows academic chairs, funds research centres, sponsors national conferences, and staffs advisory boards. This form of influence is more discreet than an envelope of cash, but infinitely more powerful. It builds careers and elevates aligned experts. In this ecosystem, certain research ideas receive priority funding, industry-friendly experts become household names, and clinical guidelines shift—often without anyone ever explicitly asking for a favourable conclusion. This institutional capture now spans every corner of healthcare”. A BMJ investigation found that 72% of leaders across 10 major medical associations had financial ties to the pharmaceutical industry. During the pandemic, Anthem Blue Cross and Blue Shield Medicaid introduced a 2020 Death Injection Provider Incentive Program, offering clinics escalating bonuses based on patient vaccination rates. Clinics reaching a 75% threshold were eligible for up to US$250 per newly vaccinated member, allowing larger practices to receive hundreds of thousands—and in some cases nearly a million—dollars. U.S. Health Secretary Robert F. Kennedy Jr. has repeatedly argued that financial incentives embedded throughout healthcare systems distort medical decision-making. In a public statement last year, Kennedy criticised reimbursement systems that rewarded hospitals and physicians for meeting pharmaceutical and vaccination-related targets. “Doctors are being paid to vaccinate, not to evaluate,” he said bluntly. https://blog.maryannedemasi.com/p/the-evolution-of-the-bribe